Phase I pharmacokinetic trial and correlative in vitro Phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1246-1250

  Alberts, David S ^a,b   Hallum, Alton V ^b   Stratton Custis, Mary ^b   Garcia, Dava J ^b   Gleason Guzman, Mary ^b   Salmon, Sydney E ^a,b   Santabarbara, Pedro ^c   Niesor, Eric J ^d   Floret, Simon ^d   Bentzen, Craig L ^d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c Ilex Oncology   (United States)

^d NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL; PHOSPHONIC ACID DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; DRUG STRUCTURE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STRUCTURE ANALYSIS; UNITED STATES;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CELL DIVISION; DIPHOSPHONATES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034908972     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
3. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer- An updated overview
4. Randomized Phase III study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): An intergroup trial (GOG, SWOG, ECOG)
5. Synthetic farnesoid X receptor (FXR) agonists: A new class of cholesterol synthesis inhibitors and antiproliferative drugs
6. Synthetic and natural activators of the nuclear receptor FXR are inhibitors of tumour cell proliferation and induce apoptosis
7. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors
8. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study